Contraceptives. On their own

Area of Science:

• Reproductive Health
• Pharmaceutical Policy
• Drug Development

Background:

• Significant unmet needs exist for safe and effective contraceptive methods.
• The United States faces substantial obstacles in contraceptive research and development.
• Private sector involvement in contraceptive innovation has declined.

Purpose of the Study:

• To explore strategies for overcoming barriers in contraceptive research and development.
• To evaluate the potential of orphan drug designation for stimulating contraceptive innovation.

Main Methods:

• Policy analysis of existing pharmaceutical incentives.
• Review of historical trends in contraceptive research funding and development.
• Assessment of the orphan drug designation framework.

Main Results:

• Contraceptive development is hindered by regulatory and market challenges.
• Orphan drug designation offers incentives like market exclusivity and tax credits.
• These incentives have historically encouraged development in other therapeutic areas.

Conclusions:

• Designating contraceptives as orphan drugs is a viable strategy to encourage private sector reentry.
• Such a policy could foster innovation and address unmet needs in reproductive health.
• Addressing research and development barriers is crucial for advancing contraceptive options.